Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infections, Human Immunodeficiency Virus and Hepatitis Clear all
Recruiting Phase 1Phase 2 Interventional

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

NCT07040319
View directory record Official record
Conditions
Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 11, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

NCT01335230
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic, HCV Coinfection
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2015 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 11, 2026, 1:19 PM EDT
Terminated Phase 4 Interventional Results available

Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

NCT00239733
View directory record Official record
Conditions
Thrombocytopenia, Hepatitis C, HIV Infections
Interventions
Anti-D
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 11, 2026, 1:19 PM EDT
Terminated Phase 4 Interventional Results available

Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

NCT00742326
View directory record Official record
Conditions
HIV, Hepatitis C, Liver Disease, Fatty Liver, Steatosis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Not applicable Interventional

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

NCT00001078
View directory record Official record
Conditions
HIV Infections
Interventions
Hepatitis A Vaccine (Inactivated)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 11, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Bakersfield, California • San Francisco, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 11, 2026, 1:19 PM EDT
Withdrawn Phase 4 Interventional

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

NCT02206932
View directory record Official record
Conditions
Hepatitis C, Chronic, HIV CDC Category A1
Interventions
Sofosbuvir + Simeprevir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911
View directory record Official record
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 11, 2026, 1:19 PM EDT
Withdrawn Phase 4 Interventional

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

NCT00782301
View directory record Official record
Conditions
Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
Interventions
maraviroc, etravirine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Clearwater, Florida • Orlando, Florida • Safety Harbor, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

NCT00023153
View directory record Official record
Conditions
HIV Infections, Chronic Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 1:19 PM EDT
Withdrawn No phase listed Observational

Immunology of HIV and Alcoholic Hepatitis

NCT03951662
View directory record Official record
Conditions
HIV/AIDS, Alcoholic Hepatitis
Interventions
Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

NCT01467531
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Hepatitis
Interventions
Dolutegravir, Rlipivirine, GSK1265744
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 11, 2026, 1:19 PM EDT
Terminated Phase 4 Interventional Results available

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

NCT01443923
View directory record Official record
Conditions
Hepatitis, HIV/AIDS
Interventions
Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

NCT00001035
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Interferon alfa-2b, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
3
States / cities
Los Angeles, California • Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Acceptability of a Vaginal Microbicide

NCT00111943
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Chronic
Interventions
1% tenofovir gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
2
States / cities
Birmingham, Alabama • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

NCT02440906
View directory record Official record
Conditions
Chronic Mental Illness, Chronic Physical Illness
Interventions
Patient-Directed Wellness Account, Health Navigator
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 55 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 11, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

NCT00142740
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 25 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
4
States / cities
Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 11, 2026, 1:19 PM EDT
Completed No phase listed Observational

Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan

NCT00001712
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV Infection
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV

NCT03652675
View directory record Official record
Conditions
Alcohol Use Disorder, HIV/AIDS, Hepatitis C, Binge Drinking
Interventions
Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of GSK1265744 Formulations

NCT01648257
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Hepatitis
Interventions
GSK1265744 Na Salt Tablets, GSK1265744 Free Acid Nanomilled Capsules, GSK1265744 Free Acid Micronized Capsules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

NCT05551273
View directory record Official record
Conditions
Hepatitis B, HIV Infections
Interventions
Selgantolimod, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Diego, California • Atlanta, Georgia • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 11, 2026, 1:19 PM EDT
Completed No phase listed Observational Results available

Hepatitis C Pharmacy-based Strategy for Injectors

NCT04698629
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 11, 2026, 1:19 PM EDT